Annals of the Rheumatic Diseases
Papers 10000
1 page of 1,000 pages (10k results)
#1Hubert MarotteH-Index: 22
Last. Stéphane Paul (Jean Monnet University)H-Index: 26
view all 5 authors...
We read with interest the paper by l’Ami et al 1 reporting the safety of a single step-down strategy without flare-up of disease in rheumatoid arthritis (RA) patients treated with adalimumab associated with high trough concentrations. At the time of personalised medicine, prediction of the absence of relapse during tapering strategy is a huge challenge to improve this approach. Furthermore, EULAR recommendations proposed in RA patients in remission without glucocorticoids to first step down the ...
1 CitationsSource
#1Chao ChengH-Index: 6
#2Jian Tian (CSU: Central South University)H-Index: 10
Last. Fang-Jie Zhang (CSU: Central South University)H-Index: 11
view all 3 authors...
We read with deep interest the article by Kloppenburg et al ,1 which was aimed at assessing the efficacy, safety, pharmacokinetics and pharmacodynamics of anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA). The results indicated that administration of 200 mg lutikizumab subcutaneously every 2 weeks for 24 weeks did not improve pain or imaging outcomes in erosive HOA compared with a placebo. This conclusion might be disappoint...
1 CitationsSource
#1Kulveer Mankia (University of Leeds)H-Index: 6
Last. Paul Emery (Leeds Teaching Hospitals NHS Trust)H-Index: 143
view all 5 authors...
We thank Deng for their interest in our study,1 in which we identified MRI interosseous tendon inflammation (ITI) in anticyclic citrullinated peptide positive at-risk individuals (CCP+ at risk) without clinical synovitis.2 Given the MRI appearances and absence of a tendon sheath on histological examination, we suggested ITI is a peritendonitis rather than a tenosynovitis. ITI was originally described as a tenosynovitis by Rowbotham et al .3 However, in the discussion, it was acknowledged that th...
#1Francesca Saccon (UNIPD: University of Padua)H-Index: 5
#2Margherita Zen (UNIPD: University of Padua)H-Index: 26
Last. Giulia FrontiniH-Index: 1
view all 18 authors...
Objectives Remission in systemic lupus erythematosus (SLE) is defined through a combination of ‘clinical SLE Disease Activity Index (cSLEDAI)=0’, ‘physician9s global assessment (PGA) Methods We tested seven potential definitions of remission in SLE patients followed-up for ≥5 years: PDN ≤5 mg/day; PGA Results We included 646 patients (mean±SD disease duration 9.2±6.9 years). At multivariate analysis, ≥2 consecutive year remission according to all definitions protected against damage (OR, 95% CI:...
1 CitationsSource
#1Debashish Mishra (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 1
#2Arghya Chattopadhyay (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 1
Last. Varun Dhir (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 10
view all 4 authors...
We read with great interest the article on ‘Gradual tapering TNF inhibitors vs conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study’1by van Mulligen et al . This was the first head-to-head comparison between two tapering strategies—biological versus conventional in rheumatoid arthritis. The final results favour tapering tumour necrosis factor inhibitors (TNFis) before conventional synthe...
1 CitationsSource
#1Elise van Mulligen (EUR: Erasmus University Rotterdam)H-Index: 1
#2Johanna M. W. Hazes (EUR: Erasmus University Rotterdam)H-Index: 46
Last. Pascal H P de Jong (EUR: Erasmus University Rotterdam)H-Index: 5
view all 4 authors...
We are pleased about the interest in our article by Mishra et al and we would like to respond to their questions so that there can be no ambiguity.1 2 First of all, there is some clarification needed on the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) that were used in combination with the TNF-inhibitors at baseline in the TApering strategies in Rheumatoid Arthritis (TARA) study. In table 1, we elaborate on the different combinations of csDMARDs that were used for each...
#1Margreet Kloppenburg (Loyola University Medical Center)H-Index: 53
#2M. Levesque (AbbVie)H-Index: 3
We thank Cheng, Tian and Zhang1 for their interest in our article2 that showed that targeting interleukin (IL)-1α and IL-1β with lutikizumab did not significantly improve clinical and imaging outcomes in patients with inflammatory erosive hand osteoarthritis (HOA). The results of the study were indeed disappointing and, appropriately, should stimulate discussion about the role of IL-1 in osteoarthritis. In our trial, levels of IL-1 were significantly reduced in subjects with erosive HOA and mode...
#1Johannes Knitza (FAU: University of Erlangen-Nuremberg)H-Index: 1
#2Lorenzo CavagnaH-Index: 24
Last. Jörg H W Distler (FAU: University of Erlangen-Nuremberg)H-Index: 61
view all 4 authors...
With great interest, we read the letter titled ‘Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria’ by Greco et al 1 published in the Annals of the Rheumatic Diseases . The authors analysed if the detection of anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies other than anti-Jo1 could improve the European League Against Rheumatism/Amercian College of Rheumatology (EULAR/ACR) classification...
2 CitationsSource
#1Anna Tjärnlund (Karolinska University Hospital)H-Index: 10
#2Ingrid E. Lundberg (Karolinska University Hospital)H-Index: 55
We have with great interest read the letter entitled ‘Response to: ‘Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria’ by Greco et al ’ by Knitza et al , to be published in the Annals of the Rheumatic Diseases .1 We appreciate the thoughtful comments made by the authors and agree on the importance of aminoacyl transfer RNA synthetase (ARS) autoantibodies, as well as other autoantibodies for correct...
We thank Marotte et al for their interest in our study and for presenting their own recent study. The Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study (STRASS) results on drug concentrations are highly valuable, as this is a large, pragmatic, randomised trial. Marotte et al found that high drug concentrations were related to lower relapse rates after 6 months of tapering.1 This is in line with our study, where we found that patients with high adalimumab concentrations could safely...
Top fields of study
Physical therapy
Rheumatoid arthritis
Diabetes mellitus